daily oral glp-1 receptor agonist orforglipron for adults with obesity FDA Grants Speedy Approval to Eli Lilly's RA Drug New GLP-1 Pill Foundayo (Orforglipron)

J Am Pharm Assoc 46(1):44-52

The hydrophobic tail of LCACs can be inserted into the membrane and may trigger the nonspecific activation of signaling pathways in the inner mitochondrial membrane to modulate its function, providing new insights into the unique mechanism of action of acylcarnitines in mitochondrial homeostasis [25]

Both can increase the risk of skin cancer

Neurotherapeutics 15, 430438

External resources for researchers PubMed BPC-157 (search) PubMed TB-500 / thymosin beta 4 (search) PubMed GHK-Cu (search) PubMed KPV (search) Related research products Disclaimer Used solely for in vitro experiments and cannot be: Used in clinical trials involving humans Administered to humans as part of an experiment or investigation Supplied to another party for human investigational use

Faseb J 2006